Gabriel H, Wilson T E, Helvie M A
Department of Radiology, University of Michigan Medical Center, Ann Arbor 48109-0326, USA.
AJR Am J Roentgenol. 1997 Jan;168(1):23-7. doi: 10.2214/ajr.168.1.8976913.
Our objective was to investigate the value of screening mammography in 65- to 74-year-old women by determining differences in various prognostic indicators in screened and nonscreened groups.
We reviewed 103 malignant breast tumors detected in 102 women 65-74 years old over a period of 73 consecutive months (February 1988-March 1994). A screening interval of less than 18 months was chosen to separate the screened from the nonscreened populations. Mammographic, histologic, and clinical features were reviewed. Statistically significant differences were calculated using Fisher's exact test and Wilcoxon's rank sum test.
Thirty-two patients were in the screened population; 70 patients were in the nonscreened population. Ninety-nine percent (102/103) of the carcinomas were apparent mammographically. We found significant differences between the screened and the non-screened groups with respect to the size of lesions revealed by mammography (11 mm versus 21 mm; p = .0002) and the incidence of minimal tumors (20/32 (63%) versus 26/70 (37%), p = .0198). The incidence of lymph node metastases was 3/27 (11%) for the screened group versus 14/47 (30%) for the nonscreened group (p = .0875). The overall positive predictive value of mammography for the 65- to 75-year-old patients was higher than in our general population, 47% versus 28%.
Screening mammography revealed significantly smaller and earlier stage tumors in 65- to 74-year-old women. This finding inferentially supports the efficacy of screening in this age population.
我们的目的是通过确定筛查组和未筛查组各种预后指标的差异,来研究65至74岁女性乳腺钼靶筛查的价值。
我们回顾了在连续73个月(1988年2月至1994年3月)期间,102名65至74岁女性中检测出的103例乳腺恶性肿瘤。选择小于18个月的筛查间隔来区分筛查人群和未筛查人群。回顾了乳腺钼靶、组织学和临床特征。使用Fisher精确检验和Wilcoxon秩和检验计算统计学上的显著差异。
32例患者属于筛查人群;70例患者属于未筛查人群。99%(102/103)的癌症在乳腺钼靶上表现明显。我们发现,筛查组和未筛查组在乳腺钼靶显示的病变大小(11毫米对21毫米;p = .0002)和微小肿瘤的发生率(20/32(63%)对26/70(37%),p = .0198)方面存在显著差异。筛查组淋巴结转移的发生率为3/27(11%),未筛查组为14/47(30%)(p = .0875)。65至75岁患者乳腺钼靶的总体阳性预测值高于我们的普通人群,分别为47%和28%。
乳腺钼靶筛查发现65至74岁女性的肿瘤明显更小且处于更早阶段。这一发现间接支持了该年龄人群筛查的有效性。